.png?width=860&height=430&name=FDA%20inspections%20under%20QMSR%20a%20guide%20to%20Compliance%20Program%207382.850%20(2).png)
Getting your device to market can feel like crossing the finish line. Your team has spent months, if not years, building toward a submission. And once the clearance or approval arrives from the Food and Drug Administration (FDA), it is only natural to feel like your mission has been accomplished.
Of course, that is not really the case. The work does not stop, but it does change. What replaces design and development is actually harder, in many cases, because post-market work is often messier and less linear than the development phase that came before it. The first 90 days on the market expose a set of commercial, operational, and regulatory realities that can be a shock to the system if this is your first time bringing a product to market.
Problems at this stage can end up costing companies a lot of time and money to resolve. So if you are nearly to submission, or have recently launched, here is what you should be thinking about.
The first sale is really two sales
Everyone knows on some level that they will need to sell their device once it is on the market. But for first-time medtech companies, what that sale actually looks like can be something of a mystery.
Take a prescription Class II device cleared through the 510(k) pathway, the profile that fits most first-time commercial medtech companies. The company's goal is probably to sell into a hospital system and get physicians and other providers to start using their device.
Getting into that hospital system, however, is not just about making a single sale. The first audience is the value analysis committee (VAC), the group inside a hospital that approves new products for purchase. The VAC includes the people who write the check, and they want two numbers: what the device costs, and what return the hospital can expect. Winning the committee is an economic argument, built on price and demonstrated value, not on clinical elegance.
But there is a second sale that needs to happen after the VAC. Here I am referring to the doctor who will actually prescribe the device, and the nurse or other provider who will use it. The first sale gets the device in the building, but the second sale puts it in use.
Clinicians may still prefer to use other, more familiar devices or treatments, and changing that behavior will take training, field support, and evidence that this device is better for patients and makes the clinician's job easier.
Field use will start rewriting the design
Real patients and clinicians will discover things about your device that no design review will ever uncover. Feedback will start to arrive within weeks of launch, and eventually patterns will begin to take shape. Perhaps a device built for right-handed use turns out to be a problem in practice, because most clinicians want their right hand free to reach for something. Or a red marking intended to guide the user reads as a warning, making them avoid the spot they were meant to touch.
That feedback is real-world evidence, and acting on it is where post-market quality work begins in earnest. Teams need to ensure that usability findings flow into the human factors file under IEC 62366, and that design changes are routed through change control, with every revision properly documented.
In essence, design controls are not finished at clearance. They have to become a continuous loop that is fed by use in the field. Teams that treat them as a pre-launch checkbox will spend the first 90 days after launch, and possibly much longer, struggling to implement changes.
Operational and logistical challenges abound
Some of the hardest first-quarter problems have nothing to do with the device and everything to do with logistics and registration.
State registration is a common surprise. A company can be fully registered with the FDA and still be unable to sell in a given state, because a number of US states maintain their own device or distributor establishment registration requirements on top of the federal ones. The discovery usually happens when a sales rep identifies a strong prospect, maybe a specialist clinic in a state the company never targeted, and then learns the company has no authority to ship there. Demand exists, and the company cannot fulfill it.
Returns and reprocessing raise a second set of questions that rarely appear in a launch plan. What happens when a hospital no longer wants the device and sends it back? If the product is designed to be reprocessed, who inspects it, cleans it, and re-boxes it to a condition fit for reuse, and how is that process documented? These are unglamorous problems, but they determine whether a company can actually deliver on the demand its sales team is working to create.
Everyone becomes part of the complaint system
Before launch, a complaint is hypothetical. After launch, complaints are a regulated input, and the obligation to capture them reaches far beyond the quality team.
Under the FDA's medical device reporting requirements in 21 CFR Part 803, a manufacturer must report deaths, serious injuries, and malfunctions once it becomes aware of them. The phrase 'becomes aware' is important here. If an employee hears, even in casual conversation with a person they just met, that someone's relative had a problem with the company's device, that information belongs in the complaint system. The duty sits with the company, which means it effectively sits with every person who works there.
Meeting that obligation takes more than a complaint form. It requires a working intake process, training for staff across sales, support, and operations, and a feedback loop that can turn complaints into corrective and preventive actions (CAPAs) when necessary.
Off-label use is both an opportunity and a liability
At some point a physician may use your device in a way you never intended and never claimed. A surgeon might find it works for a different procedure, or a clinician may apply it to a population outside the cleared indication. The clinical result might be excellent, but this is a complicated situation for you as the manufacturer.
The issue is that the cleared indications for use define what a company is legally allowed to promote. Marketing the device for an unapproved use, or handing off-label success stories to the sales team as selling points, exposes the company to serious FDA enforcement risk.
There is also a real opportunity here, but to capture it you will need to follow a specific regulatory path. You can pursue an expanded indication through a new 510(k), which converts off-label reality into an approved, promotable claim. But until that clearance comes through, the off-label use is something to document and evaluate, rather than sell on.
Is your quality system ready for the reality of post-market?
The best way to get through the immediate post-market phase is to plan ahead. But without the right electronic quality management system (eQMS), setting up complaint intake, change control, CAPA, and other key post-market surveillance processes will be a challenge in and of itself.
At Greenlight Guru, we built our eQMS specifically for medtech companies like yours, which means it comes with everything you need to be successful throughout the entire device lifecycle. From design and development to post-market surveillance, you can rely on compliant, intuitive workflows to keep your team moving and your audits easy.
If you are ready to see how Greenlight Guru can help in the first 90 days after launch and beyond, get a demo of our eQMS today.
Keep reading
If you are building out your post-market quality processes, these related guides go deeper on the specific components:
CAPA Report Template
